A Phase 1 trial of ALX-001, an investigational therapy for neurodegenerative conditions, has dosed the first patient with Parkinson’s disease. The clinical trial (NCT06309147) is assessing the safety of Allyx Therapeutics‘ ALX-001 versus a placebo when given twice a day at either 50 mg or 100 mg for…
Inoviq’s Neuro-Net technology can aid in diagnosing Parkinson’s disease at early stages, with it having effectively isolated and identified brain-released exosomes, small vesicles whose information can act as disease fingerprints, in patients’ blood, the company announced. Measuring known biomarkers of the neurodegenerative disease using this technology enriched their…
The nonprofit SPARK NS has announced the five recipients of the 2024 SPARK NS Parkinson’s Disease Translational Research Program that’s designed to foster the clinical development of promising therapies for Parkinson’s disease. The two-year program provides each scientist with up to $2 million, depending on the achievement…
The U.S. Food and Drug Administration (FDA) has agreed on the design of the upcoming Phase 2 SUNRISE-PD clinical trial to test BioVie’s oral candidate bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients. Upon a protocol review, the agency recommended including assessments of motor…
The Parkinson’s Foundation has awarded more than $1 million in 92 community-based grants across 40 states in the U.S. to improve the quality of life of people with Parkinson’s disease. This year’s funding, which ranges between $10,000 to $25,000 per organization, was awarded to programs that address local Parkinson’s…
Compounds called polyphenols in the Ecklonia cava seaweed eased motor and nonmotor symptoms in a mouse model of Parkinson’s disease, a study reports. Treatment with the polyphenols, which are natural antioxidants and anti-inflammatory agents, also prevented the loss of dopamine-producing neurons, a hallmark of Parkinson’s disease. The benefits are…
From Monterey Bay in California to Hanalei Bay in Kauai, Hawaii, Team HPP (Human Powered Potential) has rowed 2,800 miles across the Pacific Ocean and raised $28 million to benefit The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and its efforts to better treat and cure Parkinson’s disease.
Scientists at the University of Florida (UF) have developed an artificial intelligence-powered tool to help neurologists track Parkinson’s disease progression. The system analyzes video of patients’ performance on the finger-tapping test, a standard test that requires the patient to quickly tap the thumb and index finger about 10 times. It…
Home-based exercise, such as aerobic, strength, or balance exercises, helps relieve overall motor symptoms of Parkinson’s disease, according to a meta-analysis. But benefits were only seen when patients exercised for a minimum of eight weeks, and no less than 30 times. The findings provide “clinicians and patients with clear…
Scientists have discovered a new regulator — called NHR-49 — that may shed light and open potential new therapeutic avenues to prevent the formation of toxic protein clumps, a hallmark of aging-related diseases, including Parkinson’s disease. Using embryos of the roundworm Caenorhabditis elegans, they found that NHR-49 is activated…
Get regular updates to your inbox.
